Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6

Journal of Experimental Medicine

Volumn 205, Issue 5, 2008, Pages 1077-1086

  Machado, Fabiana S ^a   Esper, Lísia ^a   Dias, Alexandra ^a   Madan, Rajat ^a   Gu, YuanYuan ^a   Hildeman, David ^a   Serhan, Charles N ^b   Karp, Christopher L ^a   Aliberti, Júlio ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; INTERLEUKIN 1 RECEPTOR; LIPOXIN; PROTEASOME; SUPPRESSOR OF CYTOKINE SIGNALING 2; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; INNATE IMMUNITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TOXOPLASMOSIS; UBIQUITINATION;

ANIMALS; ASPIRIN; BRAIN; CELL NUCLEUS; IMMUNITY, NATURAL; INTERLEUKIN-10; LIPOXINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; PROTEASOME ENDOPEPTIDASE COMPLEX; SPLEEN; TNF RECEPTOR-ASSOCIATED FACTOR 2; TNF RECEPTOR-ASSOCIATED FACTOR 6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43549114554     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20072416     Document Type: Article

References (42)

1. 4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J. Exp. Med. 196:1253-1262.
2. Bafica, A., C.A. Scanga, C. Serhan, F. Machado, S. White, A. Sher, and J. Aliberti. 2005. Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J. Clin. Invest. 115:1601-1606.
3. Karp, C.L., L.M. Flick, K.W. Park, S. Softic, T.M. Greer, R. Keledjian, R. Yang, J. Uddin, W.B. Guggino, S.F. Atabani, et al. 2004. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5:388-392.
4. Kieran, N.E., P. Maderna, and C. Godson. 2004. Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney Int. 65:1145-1154.
5. Samuelsson, B. 1991. Arachidonic acid metabolism: role in inflammation. Z. Rheumatol. 50:3-6.
6. Van Dyke, T.E., and C.N. Serhan. 2003. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J. Dent. Res. 82:82-90.
7. Serhan, C.N. 2007. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25:101-137.
8. Celik, G.E., F.O. Erkekol, Z. Miotasiotarliotagil, and M. Melli. 2007. Lipoxin A(4) levels in asthma: relation with disease severity and aspirin sensitivity. Clin. Exp. Allergy. 37:1494-1501.
9. Machado, F.S., J.E. Johndrow, L. Esper, A. Dias, A. Bafica, C.N. Serhan, and J. Aliberti. 2006. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med. 12:330-334.
10. Yoshimura, A., T. Naka, and M. Kubo. 2007. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7:454-465.
11. Bradley, J.R., and J.S. Pober. 2001. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene. 20:6482-6491.
12. Chung, J.Y., Y.C. Park, H. Ye, and H. Wu. 2002. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J. Cell Sci. 115:679-688.
13. Xu, L.G., L.Y. Li, and H.B. Shu. 2004. TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis. J. Biol. Chem. 279:17278-17282.
14. Cao, Z., W.J. Henzel, and X. Gao. 1996. IRAK: a kinase associated with the interleukin-1 receptor. Science. 271:1128-1131.
15. Leo, E., K. Welsh, S. Matsuzawa, J.M. Zapata, S. Kitada, R.S. Mitchell, K.R. Ely, and J.C. Reed. 1999. Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-kappaB and Jun N-terminal kinase activation. J. Biol. Chem. 274:22414-22422.
16. Nakano, H., H. Oshima, W. Chung, L. Williams-Abbott, C.F. Ware, H. Yagita, and K. Okumura. 1996. TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor. J. Biol. Chem. 271:14661-14664.
17. Nishitoh, H., M. Saitoh, Y. Mochida, K. Takeda, H. Nakano, M. Rothe, K. Miyazono, and H. Ichijo. 1998. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol. Cell. 2:389-395.
18. Rothe, M., V. Sarma, V.M. Dixit, and D.V. Goeddel. 1995. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science. 269:1424-1427.
19. Mason, N.J., J. Fiore, T. Kobayashi, K.S. Masek, Y. Choi, and C.A. Hunter. 2004. TRAF6-dependent mitogen-activated protein kinase activation differentially regulates the production of interleukin-12 by macrophages in response to Toxoplasma gondii. Infect. Immun. 72:5662-5667.
20. Rico-Bautista, E., A. Flores-Morales, and L. Fernandez-Perez. 2006. Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions. Cytokine Growth Factor Rev. 17:431-439.
21. Kile, B.T., B.A. Schulman, W.S. Alexander, N.A. Nicola, H.M. Martin, and D.J. Hilton. 2002. The SOCS box: a tale of destruction and degradation. Trends Biochem. Sci. 27:235-241.
22. Orr, S.J., N.M. Morgan, R.J. Buick, C.R. Boyd, J. Elliott, J.F. Burrows, C.A. Jefferies, P.R. Crocker, and J.A. Johnston. 2007. SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses. J. Biol. Chem. 282:3418-3422.
23. Reis e Sousa, C., S. Hieny, T. Scharton-Kersten, D. Jankovic, H. Charest, R.N. Germain, and A. Sher. 1997. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J. Exp. Med. 186:1819-1829.
24. Bao, J., K. Sato, M. Li, Y. Gao, R. Abid, W. Aird, M. Simons, and M.J. Post. 2001. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation. Am. J. Physiol. Heart Circ. Physiol. 281:H2612-H2618.
25. Reis e Sousa, C., G. Yap, O. Schulz, N. Rogers, M. Schito, J. Aliberti, S. Hieny, and A. Sher. 1999. Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology. Immunity. 11:637-647.
26. Aliberti, J., S. Hieny, C. Reis e Sousa, C.N. Serhan, and A. Sher. 2002. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat. Immunol. 3:76-82.
27. Serhan, C.N., S.D. Brain, C.D. Buckley, D.W. Gilroy, C. Haslett, L.A. O'Neill, M. Perretti, A.G. Rossi, and J.L. Wallace. 2007. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21:325-332.
28. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y.J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767-811.
29. Aliberti, J., C. Reis e Sousa, M. Schito, S. Hieny, T. Wells, G.B. Huffnagle, and A. Sher. 2000. CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat. Immunol. 1:83-87.
30. Aliberti, J., J.G. Valenzuela, V.B. Carruthers, S. Hieny, J. Andersen, H. Charest, C. Reis e Sousa, A. Fairlamb, J.M. Ribeiro, and A. Sher. 2003. Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells. Nat. Immunol. 4:485-490.
31. Floto, R.A., P.A. MacAry, J.M. Boname, T.S. Mien, B. Kampmann, J.R. Hair, O.S. Huey, E.N. Houben, J. Pieters, C. Day, et al. 2006. Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science. 314:454-458.
32. Aliberti, J. 2005. Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma gondii. Nat. Rev. Immunol. 5:162-170.
33. Machado, F.S., and J. Aliberti. 2006. Impact of lipoxin-mediated regulation on immune response to infectious disease. Immunol. Res. 35:209-218.
34. Santiago, H.C., C.G. Feng, A. Bafica, E. Roffe, R.M. Arantes, A. Cheever, G. Taylor, L.Q. Vieira, J. Aliberti, R.T. Gazzinelli, and A. Sher. 2005. Mice deficient in LRG-47 display enhanced susceptibility to Trypanosoma cruzi infection associated with defective hemopoiesis and intracellular control of parasite growth. J. Immunol. 175:8165-8172.
35. Mackowiak, P.A. 2000. Brief history of antipyretic therapy. Clin. Infect. Dis. 31:S154-S156.
36. Vane, J.R. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231:232-235.
37. Abramson, S., H. Korchak, R. Ludewig, H. Edelson, K. Haines, R.I. Levin, R. Herman, L. Rider, S. Kimmel, and G. Weissmann. 1985. Modes of action of aspirin-like drugs. Proc. Natl. Acad. Sci. USA. 82:7227-7231.
38. Claria, J., and C.N. Serhan. 1995. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. USA. 92:9475-9479.
39. Kopp, E., and S. Ghosh. 1994. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 265:956-959.
40. Paul-Clark, M.J., T. Van Cao, N. Moradi-Bidhendi, D. Cooper, and D.W. Gilroy. 2004. 15-epi-lipoxin A 4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J. Exp. Med. 200:69-78.
41. Grunvald, E., M. Chiaramonte, S. Hieny, M. Wysocka, G. Trinchieri, S.N. Vogel, R.T. Gazzinelli, and A. Sher. 1996. Biochemical characterization and protein kinase C dependency of monokine-inducing activities of Toxoplasma gondii. Infect. Immun. 64:2010-2018.
42. Ma, X., J.M. Chow, G. Gri, G. Carra, F. Gerosa, S.F. Wolf, R. Dzialo, and G. Trinchieri. 1996. The interleukin 12 p40 gene promoter is primed by interferon γ in monocytic cells. J. Exp. Med. 183:147-157.